Empowered Funds LLC Makes New $12.27 Million Investment in Medpace Holdings, Inc. $MEDP

Empowered Funds LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 23,171 shares of the company’s stock, valued at approximately $12,271,000.

Several other large investors also recently bought and sold shares of the business. BlackRock Inc. bought a new position in Medpace during the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC raised its stake in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares during the last quarter. Madison Asset Management LLC purchased a new position in shares of Medpace in the 2nd quarter worth $128,956,000. Bank of America Corp DE bought a new stake in shares of Medpace in the second quarter worth $116,891,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 1.8%

NASDAQ:MEDP opened at $600.65 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The business’s 50-day simple moving average is $565.33 and its two-hundred day simple moving average is $494.55. The stock has a market cap of $16.76 billion, a PE ratio of 35.21, a P/E/G ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the previous year, the firm earned $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the topic of several research reports. TD Cowen raised their target price on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Royal Bank Of Canada increased their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $584.18.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the sale, the chief executive officer owned 561,195 shares of the company’s stock, valued at $347,261,854.05. The trade was a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares in the company, valued at $2,302,157.70. This represents a 65.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 133,821 shares of company stock valued at $81,748,135. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.